PE20090368A1 - Anticuerpos anti-igf - Google Patents
Anticuerpos anti-igfInfo
- Publication number
- PE20090368A1 PE20090368A1 PE2008001030A PE2008001030A PE20090368A1 PE 20090368 A1 PE20090368 A1 PE 20090368A1 PE 2008001030 A PE2008001030 A PE 2008001030A PE 2008001030 A PE2008001030 A PE 2008001030A PE 20090368 A1 PE20090368 A1 PE 20090368A1
- Authority
- PE
- Peru
- Prior art keywords
- seq
- igf
- cdr1
- cdr2
- refers
- Prior art date
Links
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 abstract 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 abstract 1
- 102000038455 IGF Type 1 Receptor Human genes 0.000 abstract 1
- 108010031794 IGF Type 1 Receptor Proteins 0.000 abstract 1
- 102000004877 Insulin Human genes 0.000 abstract 1
- 108090001061 Insulin Proteins 0.000 abstract 1
- 102000004218 Insulin-Like Growth Factor I Human genes 0.000 abstract 1
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 abstract 1
- 102000048143 Insulin-Like Growth Factor II Human genes 0.000 abstract 1
- 108090001117 Insulin-Like Growth Factor II Proteins 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 229940125396 insulin Drugs 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000002297 mitogenic effect Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000008054 signal transmission Effects 0.000 abstract 1
- 230000026683 transduction Effects 0.000 abstract 1
- 238000010361 transduction Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
SE REFIERE A UNA MOLECULA DE ANTICUERPO RECOMBINANTE QUE SE UNE A IGF-1 E IGF-2, DE MODO QUE SE IMPIDE EL ENLACE AL RECEPTOR DE IGF-1 Y SE INHIBE LA TRASMISION DE SENALES; ESTA COMPUESTA POR UNA CRD3, CDR1 Y CDR2 DE CADENA PESADA, QUE COMPRENDEN LAS SECUENCIAS SEQ ID NO:3, SEQ ID NO:1 Y SEQ ID NO:2, RESPECTIVAMENTE, Y UNA CDR3, CDR1 Y CDR2 DE CADENA LIGERA, QUE COMPRENDEN LAS SECUENCIAS SEQ ID NO:6, SEQ ID NO:4 Y SEQ ID NO:5; COMPRENDE ADEMAS UNA REGION CONSTANTE DE CADENA PESADA SELECCIONADA DE: IgG1, IgG2, IgG3, ENTRE OTRAS. SE REFIERE TAMBIEN A UN FRAGMENTO Fab, F(ab')2 Y Fv, UN VECTOR DE EXPRESION, UNA CELULA HUESPED, UN PROCEDIMIENTO DE PREPARACION Y COMPOSICION FARMACEUTICA. DICHA MOLECULA NO SE ENLAZA A LA INSULINA NI AFECTA SUS PROPIEDADES MITOGENICAS Y ENCUENTRAN SU UTILIDAD COMO AGENTES INHIBIDORES DE LAS RUTAS DE TRANSDUCCION DE SENALES MITOTICAS EN CELULAS CANCERIGENAS
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP07110587 | 2007-06-19 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20090368A1 true PE20090368A1 (es) | 2009-04-28 |
Family
ID=39154657
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2008001030A PE20090368A1 (es) | 2007-06-19 | 2008-06-17 | Anticuerpos anti-igf |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US8580254B2 (es) |
| EP (1) | EP2220119B1 (es) |
| JP (1) | JP2010531140A (es) |
| AR (1) | AR067046A1 (es) |
| CA (1) | CA2689521A1 (es) |
| CL (1) | CL2008001814A1 (es) |
| PE (1) | PE20090368A1 (es) |
| TW (1) | TW200909446A (es) |
| UY (1) | UY31160A1 (es) |
| WO (1) | WO2008155387A2 (es) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE602005013990D1 (de) | 2004-09-17 | 2009-05-28 | Eisai R&D Man Co Ltd | Medizinische zusammensetzung mit verbesserter stabilität und reduzierten gelierungseigenschaften |
| JP4989476B2 (ja) * | 2005-08-02 | 2012-08-01 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 血管新生阻害物質の効果を検定する方法 |
| AU2007252506C1 (en) | 2006-05-18 | 2012-07-19 | Eisai R & D Management Co., Ltd. | Antitumor agent for thyroid cancer |
| PE20090368A1 (es) | 2007-06-19 | 2009-04-28 | Boehringer Ingelheim Int | Anticuerpos anti-igf |
| KR101513326B1 (ko) * | 2007-11-09 | 2015-04-17 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 혈관 신생 저해 물질과 항종양성 백금 착물의 병용 |
| WO2010066868A2 (en) | 2008-12-12 | 2010-06-17 | Boehringer Ingelheim International Gmbh | Anti-igf antibodies |
| WO2010099139A2 (en) * | 2009-02-25 | 2010-09-02 | Osi Pharmaceuticals, Inc. | Combination anti-cancer therapy |
| TW201102068A (en) * | 2009-06-02 | 2011-01-16 | Novartis Ag | Treatment of ophthalmologic disorders mediated by alpha-carbonic anhydrase isoforms |
| AU2010285740C1 (en) | 2009-08-19 | 2016-03-17 | Eisai R&D Management Co., Ltd. | Quinoline derivative-containing pharmaceutical composition |
| AU2010303383B2 (en) * | 2009-10-07 | 2014-07-31 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Human domain antibodies against components of the human insulin-like growth factor (IGF) system |
| AU2014256364B2 (en) * | 2009-10-07 | 2016-07-07 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Human domain antibodies against components of the human insulin-like growth factor (IGF) system |
| ES2781299T3 (es) * | 2009-11-13 | 2020-09-01 | Daiichi Sankyo Europe Gmbh | Materiales y métodos para tratar o prevenir las enfermedades asociadas a HER-3 |
| EP2382976A1 (en) * | 2010-04-30 | 2011-11-02 | Hiroshima University | Use of pdgf-r inhibitors for the treatment of lymph node metastasis of gastric cancer |
| MX2012014776A (es) * | 2010-06-25 | 2013-01-29 | Eisai R&D Man Co Ltd | Agente antitumoral que emplea compuestos con efecto inhibidor de cinasas combinados. |
| BR112013021941B1 (pt) | 2011-04-18 | 2022-11-16 | Eisai R & D Management Co., Ltd | Agente terapêutico para tumor |
| EP3444363B1 (en) | 2011-06-03 | 2020-11-25 | Eisai R&D Management Co., Ltd. | Biomarkers for prediciting and assessing responsiveness of thyroid and kidney cancer subjects to lenvatinib compounds |
| WO2014098176A1 (ja) | 2012-12-21 | 2014-06-26 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | キノリン誘導体のアモルファス及びその製造方法 |
| US20140255413A1 (en) | 2013-03-07 | 2014-09-11 | Boehringer Ingelheim International Gmbh | Combination therapy for neoplasia treatment |
| CN105264380B (zh) | 2013-05-14 | 2017-09-05 | 卫材R&D管理有限公司 | 用于预测和评价子宫内膜癌受试者对乐伐替尼化合物响应性的生物标志 |
| US20140378401A1 (en) * | 2013-06-21 | 2014-12-25 | Gnt, Llc | Ophthalmic Lipophilic and Hydrophilic Drug Delivery Vehicle Formulations |
| US20150209426A1 (en) * | 2014-01-24 | 2015-07-30 | Boehringer Ingelheim International Gmbh | Treatment of cancer |
| ES2823756T3 (es) * | 2014-04-16 | 2021-05-10 | Signal Pharm Llc | Métodos para tratar el cáncer usando terapia de combinación de inhibidores de quinasa TOR |
| MX394386B (es) | 2014-08-28 | 2025-03-24 | Eisai R&D Man Co Ltd | Derivado de quinolina muy puro y metodo para su produccion. |
| MX385403B (es) | 2015-02-25 | 2025-03-18 | Eisai R&D Man Co Ltd | Método para suprimir el amargor de un derivado de quinoleína. |
| KR20250020678A (ko) | 2015-03-04 | 2025-02-11 | 머크 샤프 앤드 돔 엘엘씨 | 암을 치료하기 위한 pd-1 길항제 및 vegfr/fgfr/ret 티로신 키나제 억제제의 조합 |
| SG11201710198YA (en) | 2015-06-16 | 2018-01-30 | Eisai R&D Man Co Ltd | Anticancer agent |
| WO2017030161A1 (ja) | 2015-08-20 | 2017-02-23 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 腫瘍治療剤 |
| CN115737637A (zh) * | 2017-01-10 | 2023-03-07 | 王巍 | 拉索昔芬调节膜结合雌激素信号的应用及治疗癌症的方法 |
| EP3581183B1 (en) | 2017-02-08 | 2023-11-29 | Eisai R&D Management Co., Ltd. | Tumor-treating pharmaceutical composition |
| CN110831597A (zh) | 2017-05-16 | 2020-02-21 | 卫材R&D管理有限公司 | 肝细胞癌的治疗 |
Family Cites Families (83)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) * | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US4342566A (en) * | 1980-02-22 | 1982-08-03 | Scripps Clinic & Research Foundation | Solid phase anti-C3 assay for detection of immune complexes |
| NZ207842A (en) | 1983-04-25 | 1988-02-12 | Chiron Corp | Production of human insulin-like growth factor (igf) using cdna |
| WO1985000831A1 (en) | 1983-08-10 | 1985-02-28 | Amgen | Microbial expression of insulin-like growth factor |
| AU1232188A (en) | 1987-05-29 | 1988-12-01 | Mallinckrodt, Inc. | Novel pair of monoclonal antibodies to insulin-like growth factor i permits immunometric assay for igf-i |
| EP0417193B1 (en) | 1988-05-27 | 1993-08-04 | Centocor, Inc. | Freeze-dried formulation for antibody products |
| AU630882B2 (en) | 1988-06-30 | 1992-11-12 | City Of Hope | Insulinomimetic and insulin receptor binding site peptides |
| CA2058041A1 (en) | 1990-06-27 | 1991-12-28 | Katsuichi Sakano | Anti-igf-ii monoclonal antibody |
| ATE183513T1 (de) | 1993-06-03 | 1999-09-15 | Therapeutic Antibodies Inc | Herstellung von antikörperfragmenten |
| WO1995025794A1 (en) | 1994-03-23 | 1995-09-28 | Japan Clinical Laboratories | Anti-igf-i monoclonal antibody |
| US6685940B2 (en) * | 1995-07-27 | 2004-02-03 | Genentech, Inc. | Protein formulation |
| US5916771A (en) * | 1996-10-11 | 1999-06-29 | Abgenix, Inc. | Production of a multimeric protein by cell fusion method |
| US6991790B1 (en) * | 1997-06-13 | 2006-01-31 | Genentech, Inc. | Antibody formulation |
| GB9722131D0 (en) * | 1997-10-20 | 1997-12-17 | Medical Res Council | Method |
| DE69834828T2 (de) * | 1997-11-27 | 2007-01-04 | Commonwealth Scientific And Industrial Research Organisation | Verfahren zur konstruktion von agonisten und antagonisten des igf-rezeptors (1-462) |
| US6342219B1 (en) * | 1999-04-28 | 2002-01-29 | Board Of Regents, The University Of Texas System | Antibody compositions for selectively inhibiting VEGF |
| EA012079B3 (ru) * | 2001-01-05 | 2018-07-31 | Пфайзер Инк. | Моноклональное антитело к рецептору инсулиноподобного фактора роста i (igf-i) и способы его применения |
| WO2002056910A1 (en) | 2001-01-17 | 2002-07-25 | Trubion Pharmaceuticals, Inc. | Binding domain-immunoglobulin fusion proteins |
| ATE477280T1 (de) | 2001-06-28 | 2010-08-15 | Domantis Ltd | Doppelspezifischer ligand und dessen verwendung |
| US20050214857A1 (en) | 2001-12-11 | 2005-09-29 | Algonomics N.V. | Method for displaying loops from immunoglobulin domains in different contexts |
| WO2003059951A2 (fr) | 2002-01-18 | 2003-07-24 | Pierre Fabre Medicament | Anticorps anti-igf-ir et leurs applications |
| JP2003310275A (ja) | 2002-04-30 | 2003-11-05 | Kyowa Hakko Kogyo Co Ltd | ヒトインスリン様成長因子に対する遺伝子組換え抗体 |
| ES2333952T3 (es) | 2002-04-30 | 2010-03-03 | Kyowa Hakko Kirin Co., Ltd. | Anticuerpo para el factor de crecimiento humano de tipo insulinico. |
| CA2484000A1 (en) | 2002-05-24 | 2003-12-04 | Schering Corporation | Neutralizing human anti-igfr antibody |
| US7538195B2 (en) | 2002-06-14 | 2009-05-26 | Immunogen Inc. | Anti-IGF-I receptor antibody |
| US8034904B2 (en) | 2002-06-14 | 2011-10-11 | Immunogen Inc. | Anti-IGF-I receptor antibody |
| AU2003244817B2 (en) | 2002-06-28 | 2010-08-26 | Domantis Limited | Antigen-binding immunoglobulin single variable domains and dual-specific constructs |
| EP1578801A2 (en) | 2002-12-27 | 2005-09-28 | Domantis Limited | Dual specific single domain antibodies specific for a ligand and for the receptor of the ligand |
| PL378812A1 (pl) | 2003-02-13 | 2006-05-29 | Pfizer Products Inc. | Zastosowania przeciwciał przeciw receptorowi insulinopodobnego czynnika wzrostowego I |
| JP2007528201A (ja) | 2003-03-14 | 2007-10-11 | ファルマシア・コーポレーション | 癌治療のためのｉｇｆ−ｉ受容体に対する抗体 |
| ES2527871T3 (es) | 2003-05-01 | 2015-02-02 | Imclone Llc | Anticuerpos completamente humanos dirigidos contra el receptor del factor de crecimiento 1 similar a la insulina humana |
| AR046071A1 (es) | 2003-07-10 | 2005-11-23 | Hoffmann La Roche | Anticuerpos contra el receptor i del factor de crecimiento de tipo insulinico y los usos de los mismos |
| US20060263362A1 (en) | 2003-08-21 | 2006-11-23 | Atsushi Ochiai | Cancer metastasis inhibitor |
| JP4620591B2 (ja) | 2003-09-24 | 2011-01-26 | 協和発酵キリン株式会社 | ヒトインスリン様成長因子に対する遺伝子組換え抗体 |
| EP1671647A1 (en) | 2003-09-24 | 2006-06-21 | Kyowa Hakko Kogyo Co., Ltd. | Medicament for treating cancer |
| WO2005058967A2 (en) | 2003-12-16 | 2005-06-30 | Pierre Fabre Medicament | Novel anti-insulin/igf-i hybrid receptor or anti-insulin/igf-i hybrid receptor and igf-ir antibodies and uses thereof |
| WO2006008639A1 (en) | 2004-07-16 | 2006-01-26 | Pfizer Products Inc. | Combination treatment for non-hematologic malignancies using an anti-igf-1r antibody |
| MY146381A (en) | 2004-12-22 | 2012-08-15 | Amgen Inc | Compositions and methods relating relating to anti-igf-1 receptor antibodies |
| US20090123950A1 (en) | 2005-05-24 | 2009-05-14 | Morphosys Ag | Generation And Profiling Of Fully Human Hucal Gold®-Derived Therapeutic Antibodies Specific For Human CD38 |
| FR2888850B1 (fr) | 2005-07-22 | 2013-01-11 | Pf Medicament | Nouveaux anticorps anti-igf-ir et leurs applications |
| SI2860192T1 (en) | 2005-10-12 | 2018-04-30 | Morphosys Ag | Generating and profiling fully human HuCAL GOLD-specific therapeutic antibodies specific to human CD38 |
| PL1979001T3 (pl) * | 2005-12-13 | 2012-09-28 | Medimmune Ltd | Białka wiążące specyficzne dla insulinopodobnych czynników wzrostu i ich zastosowania |
| MX2008012146A (es) | 2006-03-28 | 2008-10-03 | Biogen Idec Inc | Anticuerpos anti-receptor 1 de factor de crecimiento tipo insulina (igf-1r) y uso de los mismos. |
| CN101578297A (zh) | 2006-04-07 | 2009-11-11 | 美国政府健康及人类服务部 | 治疗肿瘤疾病的抗体组合物和方法 |
| US20080014203A1 (en) | 2006-04-11 | 2008-01-17 | Silke Hansen | Antibodies against insulin-like growth factor I receptor and uses thereof |
| RU2429486C2 (ru) | 2006-06-02 | 2011-09-20 | Пфайзер Продактс Инк. | Анализ циркулирующих опухолевых клеток |
| ATE537450T1 (de) | 2006-06-30 | 2011-12-15 | Schering Corp | Igfbp2-biomarker |
| US7749966B2 (en) * | 2006-12-21 | 2010-07-06 | Boston Biomedical Research Institute | Immunological modulation of insulin-like growth factor 1 for cancer prevention/treatment and prolonging longevity |
| WO2008079849A2 (en) | 2006-12-22 | 2008-07-03 | Genentech, Inc. | Antibodies to insulin-like growth factor receptor |
| GB0702888D0 (en) | 2007-02-14 | 2007-03-28 | Glaxo Group Ltd | Novel Antibodies |
| MX2009009379A (es) | 2007-03-02 | 2009-09-14 | Amgen Inc | Metodos y composiciones para tratar enfermedades tumorales. |
| WO2008115470A2 (en) | 2007-03-16 | 2008-09-25 | East Carolina University | Hox-gene expression as a biomarker for igf-1r therapeutics |
| EA200970880A1 (ru) | 2007-03-22 | 2010-02-26 | Имклоун Элэлси | Стабильные композиции на основе антител |
| US8492328B2 (en) | 2007-05-17 | 2013-07-23 | Bristol-Myers Squibb Company | Biomarkers and methods for determining sensitivity to insulin growth factor-1 receptor modulators |
| WO2008144720A2 (en) | 2007-05-21 | 2008-11-27 | University Of Washington | Inhibitors of igf-1r signaling for the treatment of respiratory disorders |
| WO2008152422A2 (en) | 2007-06-12 | 2008-12-18 | Astrazeneca Ab | Binding proteins specific for insulin-like growth factors and uses thereof-909 |
| PE20090368A1 (es) | 2007-06-19 | 2009-04-28 | Boehringer Ingelheim Int | Anticuerpos anti-igf |
| WO2009005673A1 (en) | 2007-06-28 | 2009-01-08 | Schering Corporation | Anti-igf1r |
| US20110052667A1 (en) | 2007-06-28 | 2011-03-03 | Sylgen Laboratories, Inc. | Compositions and methods for inhibiting angiogenesis and tumorigenesis |
| JP2010535710A (ja) | 2007-07-31 | 2010-11-25 | メルク・シャープ・エンド・ドーム・コーポレイション | 細胞増殖性疾患の検出及び診断に有用なｉｇｆ−１ｒ特異抗体 |
| EP2190879A1 (en) | 2007-08-01 | 2010-06-02 | Glaxo Group Limited | Novel antibodies |
| EP2183275B1 (en) | 2007-08-03 | 2014-10-29 | Affibody AB | Igf-1r binding polypeptides and their use |
| EP2700723B1 (en) | 2007-08-06 | 2015-07-15 | Orion Genomics, LLC | Novel single nucleotide polymorphisms and combinations of novel and known polymorphisms for determining the allele-specific expression of the IGF2 gene |
| EP2190480A4 (en) | 2007-08-28 | 2013-01-23 | Biogen Idec Inc | ANTI-IGR-1R ANTIBODIES AND ITS USES |
| AU2008296386A1 (en) | 2007-08-28 | 2009-03-12 | Biogen Idec Ma Inc. | Compositions that bind multiple epitopes of IGF-1R |
| WO2009039457A1 (en) | 2007-09-19 | 2009-03-26 | The Trustees Of Boston University | Identification of novel pathways for drug development for lung disease |
| CA2694356A1 (en) | 2007-10-03 | 2009-04-09 | Osi Pharmaceuticals, Inc. | Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors |
| WO2009045361A2 (en) | 2007-10-03 | 2009-04-09 | Osi Pharmaceuticals, Inc. | Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors |
| JP2011505873A (ja) | 2007-12-18 | 2011-03-03 | シェーリング コーポレイション | 抗ｉｇｆ１ｒ療法に対する感受性のバイオマーカー |
| US20090258365A1 (en) | 2008-03-25 | 2009-10-15 | Terstappen Leon W M M | METHOD FOR DETECTING IGF1R/Chr 15 in CIRCULATING TUMOR CELLS USING FISH |
| CN102065895A (zh) | 2008-04-11 | 2011-05-18 | 比奥根艾迪克Ma公司 | 抗-igf-1r抗体和其它化合物的治疗联合 |
| JP2011519868A (ja) | 2008-05-05 | 2011-07-14 | シェーリング コーポレイション | 癌を処置するための化学療法剤の連続投与 |
| EP2296703A4 (en) | 2008-05-09 | 2012-09-05 | Dyax Corp | IGF-II / IGF-IIE BINDING PROTEINS |
| US9109026B2 (en) | 2008-06-03 | 2015-08-18 | Abbvie, Inc. | Dual variable domain immunoglobulins and uses thereof |
| MX2011003241A (es) | 2008-09-26 | 2011-04-21 | Schering Corp | Produccion de anticuerpos con alto titulo. |
| CN102164960A (zh) | 2008-09-26 | 2011-08-24 | 罗氏格黎卡特股份公司 | 双特异性抗-egfr/抗-igf-1r抗体 |
| EP2349329A4 (en) | 2008-10-14 | 2012-10-31 | Dyax Corp | USE OF IGF-II / IGF-II BINDING FOR THE TREATMENT AND PREVENTION OF SYSTEMIC SCLEROSIS ASSOCIATED WITH LUNG FIBROSIS |
| JP2012506238A (ja) | 2008-10-20 | 2012-03-15 | ザ リージェンツ オブ ザ ユニバーシティ オブ コロラド，ア ボディー コーポレイト | インスリン様増殖因子−１受容体キナーゼ阻害剤に対する抗がん反応を予測する生物学的マーカー |
| MX2011004923A (es) | 2008-11-10 | 2011-05-30 | Novartis Ag | Anticuerpos para peptidos de igf-1/e humanos modificados. |
| CA2742791A1 (en) | 2008-11-28 | 2010-06-03 | Abbott Laboratories | Stable antibody compositions and methods for stabilizing same |
| WO2010066868A2 (en) * | 2008-12-12 | 2010-06-17 | Boehringer Ingelheim International Gmbh | Anti-igf antibodies |
| WO2010069858A1 (en) | 2008-12-19 | 2010-06-24 | F. Hoffmann-La Roche Ag | Pharmaceutical composition |
| JP2012513477A (ja) | 2008-12-23 | 2012-06-14 | ソーク インスティチュート フォー バイオロジカル スタディーズ | 神経変性疾患の治療方法 |
-
2008
- 2008-06-17 PE PE2008001030A patent/PE20090368A1/es not_active Application Discontinuation
- 2008-06-18 CL CL2008001814A patent/CL2008001814A1/es unknown
- 2008-06-18 UY UY31160A patent/UY31160A1/es not_active Application Discontinuation
- 2008-06-18 AR ARP080102595A patent/AR067046A1/es unknown
- 2008-06-18 TW TW097122727A patent/TW200909446A/zh unknown
- 2008-06-19 US US12/665,373 patent/US8580254B2/en active Active
- 2008-06-19 JP JP2010512689A patent/JP2010531140A/ja active Pending
- 2008-06-19 EP EP08761223.0A patent/EP2220119B1/en not_active Not-in-force
- 2008-06-19 WO PCT/EP2008/057789 patent/WO2008155387A2/en not_active Ceased
- 2008-06-19 CA CA002689521A patent/CA2689521A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| WO2008155387A2 (en) | 2008-12-24 |
| WO2008155387A3 (en) | 2009-04-30 |
| EP2220119A2 (en) | 2010-08-25 |
| TW200909446A (en) | 2009-03-01 |
| US20100196395A1 (en) | 2010-08-05 |
| EP2220119B1 (en) | 2013-08-14 |
| US8580254B2 (en) | 2013-11-12 |
| CL2008001814A1 (es) | 2009-09-11 |
| CA2689521A1 (en) | 2008-12-24 |
| AR067046A1 (es) | 2009-09-30 |
| UY31160A1 (es) | 2009-01-30 |
| JP2010531140A (ja) | 2010-09-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20090368A1 (es) | Anticuerpos anti-igf | |
| US12398206B2 (en) | Antibodies having specificity for nectin-4 and uses thereof | |
| US20240383978A1 (en) | Bispecific binding proteins that bind cd137 and a tumor associated antigen | |
| JP2023527609A (ja) | Ｆｌｔ３結合タンパク質および使用方法 | |
| NZ592151A (en) | Anti-igf antibodies | |
| CN114507285A (zh) | Vista抗原结合分子 | |
| RU2015101803A (ru) | Перекрестно реактивные антитела к jagged 1/k jagged 2, активируемые антитела к jagged и способы их применения | |
| PE20091269A1 (es) | Moleculas de union al receptor ox40 humano | |
| ES2748021T3 (es) | Proteínas de unión a Fn14 y usos de las mismas | |
| NZ623319A (en) | Human antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereof | |
| CL2012001387A1 (es) | Anticuerpos murinos, humanizados o fragmentos de ellos anti-receptor epha2; conjugados citotoxicos; composiciones farmaceuticas que los contienen; secuencias nucleotidicas; vector; celula huesped e hibridomas que los producen y el uso de los anticuerpos en el tratamiento del cancer como en metodos de diagnostico. (divisional de sol. n° 2085-07) | |
| PE20090329A1 (es) | Anticuerpos humanizados contra el globulomero ab(20-42) y sus usos | |
| KR20220035333A (ko) | Madcam 표적 면역관용 | |
| US12012450B2 (en) | Anti-NKG2A antibodies and compositions | |
| JP2020511481A (ja) | 固形及び血液癌の治療のための併用療法 | |
| WO2022166940A1 (en) | Cldn18.2/cd3 bispecific antibodies for the therapy of cldn18.2-expressing solid tumors | |
| CN113840839B (zh) | 人源化和亲和力成熟的抗ceacam1抗体 | |
| CA3159155A1 (en) | Anti-clec-1a antibodies and antigen-binding fragment thereof | |
| Shen et al. | A novel 4-1BB/HER2 bispecific antibody shows potent antitumor activities by increasing and activating tumor-infiltrating T cells | |
| KR20250152073A (ko) | 항체, 항원 결합 단편 및 사용 방법 | |
| TWI822815B (zh) | 抗-人類ｐｄ-ｌ１之抗體及其用途 | |
| CN108473586A (zh) | 抗cd27抗体、其抗原结合片段及其医药用途 | |
| WO2025253250A1 (en) | Engineered trop2/nectin4 dual binding antibodies and uses thereof | |
| CN118234511A (zh) | 与cd137和肿瘤相关抗原结合的双特异性结合蛋白 | |
| WO2024188331A1 (zh) | 一种含pd-1/pvrig/tigit结合蛋白的药物组合物及其医药用途 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |